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A B S T R A C T
Despite therapeutic advancement in the treatment of fungal infections, morbidity and mortality caused
by these infections are still very high. There are approximately 300 fungal species that are infectious and
can cause a variety of diseases. At present, several synthetic antifungal drugs are in clinical practice, many
of them, however, are vulnerable to multidrug-resistant strains of microbes, and thus compromising the
overall treatment outcomes. Glycosides are naturally occurring plant secondary metabolites with
important therapeutic potential and clinical utility. The aim of this review was to focus on the antifungal
effects of glycosides in preclinical studies with possible mechanism(s) wherein described. Published
research show signiﬁcant susceptibility of different fungi towards phytoglycosides, mediated through
multiple mechanisms. Further detailed studies are needed to explain the clinical applications and
limitations of these glycosides.
© 2017 Elsevier Masson SAS. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 498
2. Antifungal resistance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
3. Glycosides as therapeutic agents . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
4. Preclinical status of anti-fungal glycosides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 499
5. Mechanism(s) of phytoglycosides . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506
6. Effect of sugar moiety on the antifungal activity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 506
7. Utilization of technology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507
8. Conclusions and future prospect . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507
Disclosure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 507
Available online at
ScienceDirect
www.sciencedirect.com* Corresponding authors.
E-mail addresses: hkdr2006@gmail.com (H. Khan), mmubarak@ju.edu.jo
(M.S. Mubarak).
1 Authors contributed equally to this work.
http://dx.doi.org/10.1016/j.biopha.2017.06.077
0753-3322/© 2017 Elsevier Masson SAS. All rights reserved.1. Introduction
The risk of opportunistic mycotic infections in immunocom-
promised patients, such as those affected from cancer chemother-
apy, human immunodeﬁciency virus, and organ transplantation
has increased in recent years [1]. The fungus which mostly causes
these infections in immunocompromised patients is Candida
albicans, where 90% of candidal vaginitis in these patients and
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great advances in drugs against mycotic infections, however, their
usage is limited due to side effects associated with these drugs, in
addition to the fact that Candida is becoming increasingly resistant
to antifungal medications [3]. The antifungal drug amphotericin B,
described as the ‘gold standard’ is widely used to treat serious
fungal infections, however, this drug may cause nephrotoxicity and
infusion-related reactions [4,5]. In addition, azoles antifungal
drugs produce resistant strains of Candida species. Moreover,
investigations undertaken by a number of researchers revealed
that isolates taken from women affected by Candidal vaginitis are
3.6–7.2% resistant to ﬂuconazole [6].
Surveys conducted in USA claimed that approximately 2 million
people suffer from fungal and bacterial infections each year, and
that 65% of patients acquire resistance to one of the drugs [7].
Continuous treatment and repetitive usage of antibiotics, in
addition to unsatisfactory control over infections, have led to
cases of drug treatment failure in fungal infections [8]. Due to these
problems and others, research in the ﬁeld of anti-infective
therapies, and the search for alternatives are becoming a necessity
[9,10].
Natural products have shown great promise in the discovery of
new antifungals. The recent example is enfumafungin, a
triterpene glycoside isolated from endophytic hormonema species
[11] and is a potential clinical candidate along with more potent
derivative [12]. Plants are rich sources of antimicrobial agents and
have been utilized for centuries in folk medicine to treat microbial
infections [13,14]. Furthermore, plant products used in traditional
medicines are mostly safer and may possess better disease
controlling capabilities as compared to synthetic drugs probably
owing to diverse chemistry [15–18]. Several recently published
reviews suggest that different infectious and life-threatening
diseases have been effectively treated with herbal medicines
[19,20]. Owing to their abundant availability and diversity, natural
products such as plant extracts or pure herbal medicines provide
opportunities for the discovery of new drugs [18,21,22]. As new
infectious diseases are emerging, there is a need to discover and
produce new antimicrobial agents with new mechanisms and
assorted chemical structure which are safe, efﬁcacious, and
economical [23].
2. Antifungal resistance
In recent times, antifungal resistance is a global medical
challenge for practicing physician and the number of infections
increasing drastically due to compressed immune system [24–27].
There are a number of molecular mechanisms proposed for
antifungal resistance caused by genetic modiﬁcation. As a result of
resistance to common antifungal, millions of people die from
various types of fungal infection all over the world and the
mortality rate is comparable to tuberculosis or malaria [28]. The
systemic mycoses have commonly been observed in patients with
severely impaired immune systems, people with organ or bone
marrow transplants, cancer patients undergoing chemotherapy or
in intensive care unit patients, as well as both neonates and the
elderly. Focus on novel strategies to block the emergence of drug
resistance and render resistant pathogens responsive to anti-
fungals will be critical to treating life-threatening fungal infec-
tions. To encounter all these unavoidable situations, adaptation of
novel strategies are highly required to improved the efﬁcacy and
safety and thus patient compliance [29–31]. For this purpose,
several sources are used to designed more effective molecules with
better tolerability against resistance by using modern drug
delivery system [32–35].3. Glycosides as therapeutic agents
Glycosides are compounds in which a sugar molecule is
attached, via a glycosidic linkage, to the anomeric carbon of a
non-sugar moiety. Certain enzymes present in the body can
activate some of glycosides through hydrolysis, by removing its
sugar molecule. These activated molecules can then act on speciﬁc
targets, hence they are used as medicines and thus glycosylation
affects both the hydrophobicity and biological activity of plant
natural products [36,37]. However, most are active in glycosylated
form. In recent times, glycosides have shown dynamic potential as
therapeutic agents in the treatment of different disorders. Some of
them includes anticancer [38], antithrombotic and antidiabetic
[39,40], protective effect in myocardial injury [41], antioxidant
[42], antiviral [43], antidepressant like effect [44,45], antimalarial
[46], antifungal [47], antiplatelet [48]. Accordingly, this review
provides comprehensive information on the subject of preclinical
status of glycosides isolated from various plants as possible
candidates for clinical studies to discover better, safer, and more
effective treatments against drug-resistant fungi.
4. Preclinical status of anti-fungal glycosides
Several research groups have been involved in the isolation and
identiﬁcation of antifungal activities of glycosides of plant origin
(Table 1). In 1988, Hufford et al. isolated pure triterpene acetylated
saponins, dioscin 1 with minimum inhibitory concentration (MIC)
of 1.56 mg/mL, and pennogenin rhamnosyl chacotrioside 2 (MIC =
6.25 mg/mL) from Trillium grandiﬂorum; these compounds exhib-
ited strong activity against Candida parapsilosis and Candida albican
[49], Trichosporon. beigelii, and Malassezia. furfur [50]. On the other
hand, Carmely et al. isolated a new 4-methylated steroidal
glycoside (Eryloside A 3) from Erylus lendenfeldi which displayed
signiﬁcant antifungal activity against Candida albicans (MIC
15.6 mg/mL) [51]. A new antifungal glycoside, 3-O[a-L-arabinopyr-
anosyl(1–2)][a-L-arabinopyranosyl(1–6)]2-acetoami do-2-deoxy-
b-D-gluco-pyranosyl oleanolic acid 4 has been isolated from
Pithecelobium racemosum by Khan and colleagues; this glycoside
displayed remarkable potency against Trichophyton mentogro-
phytes, Candida albicans and Sacharomyces cerevisiae with MIC
values of 6.25, 12.5 and 12.5 mg/mL, respectively [52].
In addition, researchers isolated the new aurantoside D 5, E, and
aurantoside F 6, which are polyene tetramic acids comprising an N-
trisaccharide unit, from the ethanol extract of the marine sponge of
Siliquaria spongia japonica. These researchers found that auranto-
sides D and E were active against Aspergillus fumigatus and Candida
albicans, whereas F was inactive. Moreover, aurantosides D and E
were found to exhibit potent antifungal activity against Aspergillus
fumigatus and Candida albicans, with MIC values of 9.5 and 9.7 mg/
mL, respectively, against Candida albicans, and MIC values of 11.0
and 13.6 mg/mL, respectively, against Aspergillus fumigatus [53].
Furthermore, results from this investigation revealed that auranto-
sides E and F were signiﬁcantly active against the spore
germination of rice blast fungus Magnaporthe grisea. Similarly,
the antifungal activity of monodesmosides, isolated from the
leaves of Kalopanax pictum, was investigated by Lee et al. [54].
These researchers observed that the monodesmosides a-hederin 7,
sapindoside B 8 and sapindoside C 9 exhibit marked antifungal
activity against Microsporum canis, Candida immeritis, Trichophyton
mentagrophytes, Cryptococcus neoformans, and Candida albicans
with MIC values of 6.25–25 mg/mL. Furthermore, the aerial parts of
Phlomis samia led to the isolation of a new phenylethanoid
glycoside 1-O-3,4-(dihydroxyphenyl)ethyl b-D-apiofuranosyl-
(1 !4)-a-L-rhamnopyranosyl-(1 !3)-4-O-caffeoyl-b-D-glucopyr-
anoside called samioside 10 which displayed effective antifungal
Table 1
Plant derived glycosides with antifungal activities.
Plant name Chemical Structure Reference
Trillium grandiﬂorum [49,50]
Erylus lendenfeldi [51]
Pithecelobium racemosum [52]
Siliquaria spongia [53]
Kalopanax pictum [54]
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Table 1 (Continued)
Plant name Chemical Structure Reference
Phlomis samia [55]
Chenopodium quinoa [56]
Gmelina arborea [57]
Yucca gloriosa [58]
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Table 1 (Continued)
Plant name Chemical Structure Reference
Ribulus terrestris [59]
[60]
Gleditsia sinensis [61]
Saussurea lappa [62]
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Table 1 (Continued)
Plant name Chemical Structure Reference
Sapindus saponaria [63]
Vitex negundo [64]
Gardenia jasminosides [65]
Peperomia pellucida [66]
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Table 1 (Continued)
Plant name Chemical Structure Reference
Cynanchum wilfordii [67]
Callianthemum taipaicum [68]
Trillium govanianum [69]
Acacia ataxacantha [70]
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Table 1 (Continued)
Plant name Chemical Structure Reference
Bidens pilosa [71]
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glabrata, and Candida tropicalis [55].
In addition, the following compounds isolated by Woldemi-
chael and Wink from Chenopodium quinoa, showed antifungal
activity against Candida albicans: 3-O-b-D-glucuronopyranosyl
oleanolic acid 28-O-b-D-glucopyranosyl ester 11 (MIC  500 mg/
mL), 3-O-a-L-arabinopyranosyl hederagenin 28-O-b-D-glucopyr-
anosyl ester 12 (MIC  500 mg/mL), 3-O-b-D-glucopyranosyl-
(1 !3)-a-Larabinopyranosyl hederagenin 28-O-b-D-glucopyrano-
syl ester 13 (MIC  500 mg/mL), 3-O-a-L-arabinopyranosyl phyto-
laccagenic acid 28-O-b-D-glucopyranosyl ester 14 (MIC = > 500 mg/
mL), 3-O-b-D-glucopyranosyl-(1 !3)-a-L-arabinopyran osyl phy-
tolaccagenic acid 28-O-b-D-glucopyranosyl ester 15 ((MIC = 100
mg/mL), 3-O-b-D-glucopyranosyl-(1 !3)-a-L-arabinopyranosyl
phytolaccagenic acid 16 (MIC 500 mg/mL) [56]. A number of
publications pertaining to the isolation and antifungal activity of
glycosides have appeared in the literature. Kawamura and Ohara
isolated four iridoid glycosides, catalpol 17 6-O-a-L-(2”-O-trans-
cinnamoyl) rhamnopyranosylcatalpol 18, 6-O-a-L-(3”-O-trans-
cinnamoyl)rhamno-pyranosylcatalpol, 19 and 6-O-a-L-(4”-O-
trans-cinnamoyl) rhamnopyranosylcatalpol 20 from the methanol
extract of the heartwood of Gmelina arborea [57]. These
researchers have also studied the antifungal activity of isolated
compounds against a yeast that causes skin infection called tinea
versicolor and found that isolated iridoid glycosides display
signiﬁcant antifungal activity with catalpol being most potent
(MIC 0.05 mmol/mL). On the other hand, work by Favel et al. on
Yucca gloriosa ﬂowers led to the isolation of two spirostanol
glycosides, yuccaloeside B 21 and yuccaloeside C 22. In vitro
antifungal activity against a panel of human pathogenic fungi,
yeasts as well as dermatophytes and ﬁlamentous species, revealed
that these two isolated glycosides exhibit broad antifungal activity
against all studied strains except for Candida lusitaniae and Candida
kefyr with MIC between 0.39 and 6.25 mg/mL [58]. While in
phytochemical study of Ribulus terrestris, Zhang et al. in 2006,
isolated a number of saponins glycosides [59], in which Tigogenin-
3-O-b-D-xylopyranosyl (1 !2)-[b-D-xylopyranosyl (1 !3)]-b-D-
glucopyranosyl (1 !4)-[a-L-rhamnopyranosyl (1 !2)]-b-D-galac-
topyranoside 23 and Tigogenin-3-O-b-D-glucopyranosyl (1 ! 2)-
[b-D-xylopyranosyl (1 !3)]-b-D-glucopyranosyl (1 !4)-b-D-gal-
actopyranoside 24 showed marked antifungal activity against
various test fungi. The marked effects of these compounds in
comparison to others isolate, it is assumed that spirostanol
skeleton and the number of oligosaccharide residue attached at C-
3 of aglycon, are primary for the antifungal. however, carbonyl base
at C-12 needs further study to ascertain its relationship with the
antifungal action.
Similarly, Sobolewska and colleagues (2006) isolated antifungal
steroidal glycosides named as (25R)-spirost-5-en-3b-ol 3-O-
a-rhamnopyranosyl-(1 !4)-a-rhamnopyranosyl-(1 !4)-[a-rhamnopyranosyl-(1 !2)]-glucopyranoside 25 [60]. It exhibits
antifungal potency with MIC = 200 mg/mL. In addition, Zhou and
colleagues isolated two ellagic acid glycosides, a new compound,
3-O-methylellagic acid-40-(50 0-acetyl)-a-L-arabinofuranoside 26
and a previously known compound, 3-O-methylellagic acid-40-
O-a-L-rhamnopyranoside 27 from the ethanol extract of Gleditsia
sinensis spines. These two compounds played signiﬁcant antifungal
activity against the spore germination of rice blast fungus
Magnaporthe grisea, with IC50 values of 13.56 and 16.14 mg/mL,
respectively [61]. In a similar study, Rao et al. isolated four new
acylated ﬂavonoid glycosides from the roots of Saussurea lappa; 30-
(3R-acetoxy-5,5-dimethylcyclopent-1-ene)-40-O-methylscutellar-
ein-7-O-(60 0 0 0-Oacetyl-b-D-glucopyranosyl-(1 !3)-[a-L-rhamno-
pyranosyl-(1 !2)]-b-D-glucopyranoside, 28, kaempferol-3-O-
b-D-glucopyransoyl-(1 !4)-a-L-rhamnopyran osyl-(1 !6)-b-D-
galactopyranoside-7-O-(60 0 0 0-O-acetyl-b-D-glucopyranosyl(1 !3)-
[a-L-rhamnopyr anosyl-(1 !2)]-b-D-glucopyranoside 29, kaemp-
ferol-3-O-b-D-glucopyranosyl(1 !2)-b-D-(6a0-O-caffeoyl)-gluco-
pyranoside-7-O-(60 0 0 0-O-acetyl-b-D-glucopyranosyl-(1 !3)-[a-L-
rhamnopyrano syl-(1 !2)]-b-D-glucopyranoside 30, and kaemp-
ferol-3-O-a-L-(2a0,3a0-E-di-p-coumaroyl-p-coumaroyl)-rhamno-
side-7-O-)-rhamnoside-7-O-(60 0 0 0-O-acetyl-b-D-glucopyranosyl-
(1 !3)-[a-L-rhamnopyranosyl-(1 !2)]-b-D-gluco pyranoside 31.
These isolated glycosides were bioassay against nine fungi:
Aspergillus niger, Aspergillus Ochraceus, Aspergillus versicolor,
Aspergillus ﬂavus, Penicillium ochrochloron, Penicillium funiculosum,
Trichoderma viride, Cladosporium cladosporioides, and Alternaria
alternate. Results revealed greater antifungal activity than the
commercial drug miconazole [62].
In an investigation conducted by Tsuzuki et al., two pure
triterpene acetylated saponins, 3-O-(4-acetyl-b-D-xylopyranosyl)-
(1 !3)-a-L-rhamno pyranosyl-(1 ! 2)-a-L-arabinopyranosyl-
hederagenin 32 and 3-O-(3,4-di-acetyl-b-D-xylopyrano syl)-
(1 !3)-a-L-rhamnopyranosyl-(1 ! 2)-a-L-arabinopyranosyl-
hederagenin 33 were isolated from Sapindus saponaria. These two
compounds, in addition to extracts from dried fruits of the plant,
were investigated for their antifungal activity against clinical
isolates of yeasts Candida albicans and non-Candida albicans from
vaginal secretions of women with vulvovaginal candidiasis. Results
from this study showed that isolated compounds exhibit strong
activity against Candida parapsilosis [63]. Similarly, Sathiamoorthy
and co-researchers isolated a new ﬂavone glycoside 4',5,7-
trihydroxy-3'-O-b-D-glucuronic acid-6”-methyl ester 34 from leaf
ethanol extract of Vitex negundo with high potency against both
Trichophyton mentagrophytes and Cryptococcus neoformans (MIC =
6.25 mg/mL) [64]. Interestingly, Lelono et al. identiﬁed two
antifungal compounds, genipin and geniposide from the methanol
extract of leaves and stems of Gardenia jasminosides. These two
compounds displayed remarkable antifungal activity against a
wood rotting fungus Pleurotus ostreatus [65]. In addition, research
Fig. 1. Proposed antifungal mechanisms of plant glycosides.
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exhibit effective antifungal effect against pathogenic fungi,
Fusarium oxysporum and Candida cassiicola. Structure activity
relationship (SAR) studies suggest that the lactone group present
in these compounds may be responsible for their antifungal
activity because it penetrates fungal cells and reacts with
sulphydryl group. In addition, phytochemical analysis led to the
isolation of xanthone glycoside, patuloside A 37 from the leaves of
Peperomia pellucida [66].
Furthermore, two new pregnane glycosides, wilfoside K1GG 38
and wilfoside C1GG 39, along with four known compounds,
wilfoside C1N, wilfoside K1N 40, cynauricuoside A, and wilfoside
C1G were isolated from the methanol extract of the dried roots of
Cynanchum wilfordii by Yoon et al. [67]. These compounds were
investigated for antifungal activity against barley powdery mildew
caused by Blumeria graminis f. sp. hordei. Results indicated that
caudatin glycosides display stronger activity, whereas kidjoranine
glycosides exhibit weaker antifungal activity than positive control
polyoxin B. In a paper recently published, Wang and his co-
workers, isolated a new ﬂavanol glycoside, isorhamnetin-3-O-a-L-
arabinoside-7-O-b-D-glucoside, from Callianthemum taipaicum.
This glycoside showed antifungal activity against Rhizoctonia
cerealis (MIC 1.92 mg/mL), Botrytis cinerrea (MIC 1.38 mg/mL), and
Thanatephorus cucumeris (MIC 1.39 mg/mL) [68]. Similarly, Ismail
and colleagues identiﬁed a new spirostane steroidal saponin,
govanoside A, along with known compounds, borassoside E 42, and
pennogenin 43, from the rhizomes of Trillium govanianum. Studies
showed that C. albicans was highly susceptible to govanoside A
(MIC = 5.0 mg/mL) and borassoside E pennogenin (MIC = 2.5 mg/
mL) [69]. Most recently, Amoussa et al. (2016) isolated a new
glycoside with the name of acthaside 44 from Acacia ataxacantha
[70]. In the antimicrobial assay, it showed antifungal activity
against Candida albicans with MIC 25 and MFC 50 mg/mL.
Additionally, 44 caused signiﬁcant free radical scavenging effect
which further potentiate its therapeutic potential. Likewise,
cytopiloyne 45 a glycoside isolated from Bidens pilosa with
multiple medicinal uses in traditional system of treatment [71].
When studied for detail antifungal activity with possible mecha-
nism, it showed marked effects were observed.
5. Mechanism(s) of phytoglycosides
Researchers around the world have extensively investigated the
underlying mechanisms for antifungal sensitivity of phytoglyco-
sides (Fig. 1).
On their work on the methanol extract of seeds of Chenopodium
quinoa, Woldemichael and Wink isolated at least 16 saponins.
These researchers evaluated the antifungal activity of these
compounds against Candida albicans and hemolytic activity on
erythrocytes. Results revealed that these compounds and derived
monodesmosides, bidesmosides and derived monodesmosides
display little or no antifungal activity, whereas monodesmosides
exhibit higher degree of hemolytic activity. They concluded that
monodesmoside saponins, having oleanolic acid and hederagenin
as aglycon, are highly hemolytic and exhibit higher antimycotic
activity [56]. On the other hand, Favel et al. suggested the
antimycotic properties of spirostanol glycosides are attributed to
their ability to complex with sterols of fungal membranes, which
produce spore-like structures that lead to rupture of the
membrane leading to fungal cell death [58]. Similar results were
obtained by Lunga and colleagues after they investigated the
phytochemical analysis of seeds of Hyocyamus niger L. and ascribed
the antifungal activity of these compounds to formation of
complex with sterols in fungal membranes which causes pore
formations in membrane and loss in membrane integrity [72].
Similarly, results from an investigation by Zhang et al. showed thatthe mechanism of antifungal glycosides was damaging of the
plasma membrane and leakage of cytoplasmic material which
leads to cell death [59]. Similarly, with the aid of ﬂow cytometric
analysis, Park et al. evaluated the antifungal activity of styraxja-
ponoside A and B, antifungal lignan glycosides extracted from the
stem bark of S .japonica, against a number of human pathogenic
fungal strains. They attributed the activity to membrane–disrup-
tion mechanisms [73]. Likewise, a recent review by Freiesleben and
Jäger suggested the mechanism of action of steryl glycosides is
through cell membrane disruption. After complex formation with
cholesterol, they attach to lipophilic moiety inside the membrane
and hydrophilic moiety outside the cell, and hence suppress the
growth of fungi [74].
On the other hand, Shrestha et al. ascribed the antifungal
property of glycosides to increasing plasma membrane permeabil-
ity, that causes leakage of pre-loaded calcein from 50% of small
unilamellar vesicles with sterol and glycerophospholipid compo-
sition of the plasma membrane of Sacharomyces cerevisiae [75]. Lee
and colleagues reported that the antifungal activity of magnoloside
A against various Cryptococcus species, is due to its inhibition of the
calcineurin pathway. Calcineurin is a highly speciﬁc, Ca2+-depen-
dent serinethreonine phosphatase which has an important role in
mediating cell stress responses [76]. Other researchers have also
inferred involvement of calcineurin pathway in the growth and
pathogenesis of several fungal species, such as C. albicans,
Cryptococcus neoformans, and Aspergillus fumigatus, in diseases
caused by fungal infections [77]. Based on the various mechanisms
described/reported for the phytoglycosides as antifungal agents
reveled that their actions mediated through different and multiple
targets, therefore, it can be assumed that they may be more
resistant to fungal modiﬁcations for drug resistance. To know the
answer of such questions, further detail studies are required.
6. Effect of sugar moiety on the antifungal activity
Sugar (glycone) part in glycosides are mostly inactive in terms
of activity but sometime crucial for the overall effect. For instance,
monodesmoside saponins, having oleanolic acid and hederagenin
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activity. Furthermore, addition of a glucose unit on the C-3 chain,
and introduction of an additional carboxy group on ring E
dramatically reduce hemolytic activity because hydrophobic
interactions with membrane lipids become reduced [56].
SAR studies revealed that the stronger activity of caudatin
glycosides is due to the presence of an ikemaoyl group at C-12,
whereas kidjoranine glycosides have cinnamoyl group [67].
Additionally, the antimycotic action of the pregnane glycosides
was increased by removal of a sugar moiety at C-3. Results also
showed that patuloside A (MIC = 18.24 mg/mL) has weak antifungal
activities against Aspergillus ﬂavus and Candida albicans.
Quite recently, Ismail and colleagues reported that pharmaco-
logical activity of antifungal compounds was affected by the
number of sugar moieties linked with the aglycon portion of
steroidal nuclei. For example the antifungal activity of govanoside
A having ﬁve sugar units is less, as compared to borassoside E with
three sugar units. They concluded that a high number of sugar
units increases polarity of the glycoside, and hence makes it
difﬁcult to cross fungal membranes [69].
7. Utilization of technology
Drug development is greatly facilitated by the recent advance-
ment in technologies and genetic studies [35,78,79]. For instance,
studies have shown members of the ALS gene family encoding
adhesins play an important role for interactions of C. albicans with
host tissues [80]. Similarly, the epithelial adhesin (EPA) gene family
account for the largest group in C. glabrata, comprising at least 23
related genes, most of them located in subtelomeric regions
[81,82]. The primary EPA including, Epa1, Epa6 and Epa7, display
different binding speciﬁcities concerning decoration of host cell
ligands containing a terminal galactose residue [83,84]. The
computational studies also have provided a strong theoretical
foundation for the correlation of biological system with computer
based results [85–87] and thus play a signiﬁcant in overall new
drug discovery. The major advantage of such techniques is
theoretical modiﬁcation of results and thus derisible outcome
can be achieved.
Additionally, the introduction of different dosage forms have
improved therapeutic outcomes and ultimate results [88]. The
nanotechnologies are widely used for the rectiﬁcation of various
pharmacokinetic limitations in drug candidates from natural
sources [10,89]. In recent years, nanotechnology has driven efforts
toward this therapeutic area, proposing efﬁcient colloidal (nano-
sized) delivery systems (NDDS) that have attained in some cases a
market signiﬁcance and clinical relevance. NDDS can control the
release of loaded drugs or target their distribution within the body,
focusing selectively their activity in the infected cells, thus
reducing side effects. Loading of antifungals including food
materials, in nanocarriers through physical encapsulation, adsorp-
tion, or chemical conjugation, makes it possible to overwhelm
their poor solubility and improve pharmacokinetics and thera-
peutic index, compared to the neat drugs [90–92].
8. Conclusions and future prospect
This review covers glycosides derived from medicinal plants,
which are traditionally used for the treatment of fungal diseases.
Results showed that isolated plant glycosides exhibited profound
sensitivity against various fungi and the effects were not limited to
one particular plant family or class of glycosides. These outstand-
ing preclinical results deserve the utmost attention of pharma-
industry for further detail studies to move towards some
conclusions and identiﬁcation of clinically useful agents. In
addition, mechanistic studies revealed that these naturalglycosides exert their effects through multiple mechanisms, unlike
synthetic standard antifungal agents such as amphotericin B,
which acts by binding to the sterol component of a cell membrane,
leading to alterations in cell permeability and cell death, or
ﬂuconazole which is a highly selective inhibitor of fungal
cytochrome P450 dependent enzyme lanosterol 14-a-demethy-
lase for fungistatic effect, and thus having numerous side effects.
While considering the different sites of antifungal action/
mechanisms, it could be assumed that these glycosides might be
less proven to resistance and have better tolerability to cope with
the current emergence of resistant to various synthetic agents.
Moreover, the latest development in the drug discovery techniques
for natural product further encourages researchers to work on the
isolation and characterization of phytopharmaceuticals that could
lead to some outstanding hits. In this connection, these prelimi-
nary effects need further detailed studies including mechanism
exploration, safety proﬁle and clinical trials for the discovery of
clinically useful drugs.
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